Pfizer has committed to investing a substantial amount of money in the development of treatments to address the imminent threat of a “heart failure pandemic.” This decision comes as cases of myocarditis and sudden cardiac deaths continue to rise, posing a significant challenge.
In order to bolster their efforts, the renowned Covid mRNA vaccine manufacturer has recently acquired several companies, including Arena Pharmaceuticals, through a significant cash acquisition of $6.7 billion. Arena Pharmaceuticals specializes in the development of treatments for heart inflammation conditions such as myocarditis and pericarditis. With the surge in heart failure cases, Pfizer is projected to generate substantial profits, potentially reaching tens of billions of dollars.
This anticipated success is attributed to the decline in sales of their Covid vaccines, prompting the company to capitalize on the growing demand for heart failure treatments. Concurrently, scientists have issued warnings about the potential of the latest Covid variant to trigger a widespread “heart failure pandemic.”
The investigation on the recently discovered variant called JN.1 has raised concerns about a potential worldwide healthcare threat associated with COVID-19.
According to scientists, this particular strain of the virus has the potential to trigger a widespread outbreak of heart failure.
Health professionals have cautioned that individuals who contract the disease are at a higher risk of experiencing heart-related complications.
The emergence of the new JN.1 variant has resulted in a surge of COVID-19 cases in multiple countries.
Scientists assert that these new variants are accountable for the sudden increase in fatal heart failure cases that began in 2021.
In recent weeks, there has been a surge in heart failure cases in several countries, including the US, UK, China, and India. A new report from Japan’s leading research institute, Riken, has now raised concerns about this issue. According to the report, the ACE2 receptors, which the coronavirus attaches to in human cells, are highly prevalent in the heart. Consequently, the scientists argue that individuals who contract the virus may experience a decline in cardiac function. Health officials are cautioning that with the simultaneous rise in flu cases, this winter could witness a substantial upsurge in illness instances.
The report states:
“Even though conclusive clinical evidence that persistent SARS-CoV-2 infection is associated with declined cardiac function has not been reported so far, the proof-of-concept study of the possibility of SARS-CoV-2 persistent infection of the heart and the potential risk of opportunistic progression of heart failure should be validated by a three-dimensional human cardiac tissue model which would serve as the alarm bell for a global healthcare risk.”